The risk of having suicidal impulses is higher for semaglutide than for other weight-control drugs, according to a new study. This was especially true for those also taking antidepressants or benzodiazepines.
āThis study using the WHO database found a signal of semaglutide-associated suicidal ideation, which warrants urgent clarification,ā the researchers write. āBased on these findings, we believe that a precaution of use in patients with psychiatric disorders or psychological lability could be added in the semaglutide package insert.ā
The research was conducted by an international team led by Georgios Schoretsanitis at the Zucker School of Medicine at Northwell/Hofstra, New York, and the University of Zurich, Switzerland, and Chiara Gastaldon at the WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation at the University of Verona, Italy, and the University of Bern, Switzerland. It was published in JAMA Network Open.
You've landed on a MIA journalism article that is funded by MIA supporters. To read the full article, sign up as a MIA Supporter. All active donors get full access to all MIA content, and free passes to all Mad in America events.
Current MIA supporters can log in below.(If you can't afford to support MIA in this way, email us at [email protected] and we will provide you with access to all donor-supported content.)
